Form 4: Terns Pharmaceuticals Director Jill Quigley Granted 45,000 Stock Options

Terns Pharmaceuticals, Inc. Director Jill M. Quigley was granted 45,000 stock options with an exercise price of $4.10, aligning her incentives with long-term shareholder value.

Summary

• Jill M. Quigley, a Director of Terns Pharmaceuticals, Inc. (TERN), was granted 45,000 stock options on June 11, 2025.
• The stock options have an exercise price of $4.10 per share.
• These options will vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or immediately prior to the Annual Meeting following the grant date.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Ms. Quigley directly beneficially owns 45,000 derivative securities (stock options) in Terns Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a standard compensation practice that aligns the interests of a director with shareholders through long-term incentives. It is not a major operational or financial announcement but indicates stable corporate governance and incentivized leadership.

Positives

• The grant of 45,000 stock options to Director Jill M. Quigley aligns her financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The defined exercise price of $4.10 provides a clear benchmark for the options' potential value, reflecting a commitment to future growth.

Negatives

• No negative information is typically disclosed in a Form 4 filing, as it primarily reports routine insider transactions and compensation.

Risks

• This Form 4 filing does not contain information regarding company-specific operational or financial risks.

Future Outlook

The stock options granted to Director Jill M. Quigley are structured to vest in full on the earlier of the first anniversary of the grant date (June 11, 2025) or immediately prior to the Annual Meeting following the grant date, indicating a future incentive structure tied to continued service and company performance.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of executive and director compensation to align leadership incentives with long-term shareholder value creation and retention of key talent.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly within the biotechnology sector, where long-term incentives are crucial for retaining talent and driving innovation.
• While this document does not provide specific comparative data, the number of options granted and the exercise price would typically be benchmarked against peer companies of similar market capitalization and development stage to ensure competitive compensation.

Related Party Transactions

• This document reports a compensation-related transaction (stock option grant) to a director, which is a standard related-party transaction in the context of corporate governance and executive compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their incentives with shareholder value creation, potentially leading to better long-term company performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will vest in full on the earlier of June 11, 2026 (the first anniversary of the grant date) or immediately prior to the Annual Meeting following the grant date.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, stock options, insider transaction, Form 4, beneficial ownership, director compensation, Jill M. Quigley